Replies to post #129962 on Biotech Values

[biomaven0]

I guess I don't really understand his point. If you are going after accelerated approval based on some surrogate endpoint, then you have to demonstrate that the patients in the trial have failed all available therapies (cf. T-DM1). But with OS as an endpoint that is no longer needed.

Peter